The CodeBreaK 200 trial revealed that sotorasib significantly improved PFS and had a more promising safety profile compared with docetaxel, in patients with advanced KRAS G12C NSCLC treated previously with other anticancer drugs. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.